OTCM
VIVXF
Market cap0USD
Dec 12, Last price
0.00USD
Name
Avivagen Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Avivagen Inc. is a life sciences enterprise that invents and sells specialized products, primarily for animal feed, aimed at bolstering the immune systems of livestock. These solutions are designed to enhance animals' health, leading to improved growth and overall productivity. The company's diverse product lineup features OxC-beta Livestock, a crucial premix for farm animal diets. Beyond agriculture, Avivagen also manufactures health supplements such as Vivamune and Dr. Tobias-branded chews for dogs, along with the Dr. Tobias Beta blend, formulated to support human immunity. Established in 2005 and based in Ottawa, Canada, Avivagen Inc. distributes its offerings across numerous international markets, including the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia.
Key people
G.F. Kym Anthony
Chief Executive Officer, Vice Chairman of the Board · since 2023
Ira Levy
Interim Chief Financial Officer · since 2022
James Nickerson
Executive Vice President - Business Development and Product Innovation · since 2023
Graham Burton
Chief Scientific Officer, Director · since 2017
David Hankinson
Independent Chairman of the Board · since 2023
Paul Mesburis
Independent Director · since 2019
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | 2017‑10 | 2016‑10 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||